세계의 울혈성심부전 치료제 시장 : 유형별, 약물 종류별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Congestive Heart Failure Drugs Market, By Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,535,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,488,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,884,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 울혈성심부전 치료제 시장 규모는 2022년 66억 90만 달러로 2023년부터 2030년까지 15.8%의 CAGR로 확대될 것으로 예상됩니다.

울혈성심부전 치료제 시장 - 시장 역학

• 고령 인구의 증가, 고혈압, 비만, 당뇨병 발병률의 증가는 산업의 성장을 증가시킬 것으로 예상됩니다.
• 노인은 동반 질환이 많고 많은 약물을 자주 복용하기 때문에 약물 상호 작용과 심부전을 악화시키는 상태에 빠지기 쉽습니다. 비만은 수면무호흡증, 당뇨병 등 다른 건강 문제와도 관련이 있으며, 모두 심부전 위험을 높입니다. 세계보건기구(WHO)에 따르면 2020년에는 5세 미만 어린이 중 3,900만 명이 과체중 또는 비만이 될 것입니다. 신흥 경제국의 의료 인프라가 발전함에 따라 현대 의료, 특히 CHF와 같은 질병에 대한 약물 치료에 대한 필요성이 증가하여 시장에 성장 기회를 제공하고 있습니다. 그러나 심장 재동기화 요법(CRT) 및 기타 의료기기와 같은 첨단 치료법은 때때로 의약품의 필요성을 줄일 수 있습니다.

울혈성심부전 치료제 시장 - 세분화 분석

• 세계 울혈성심부전 치료제 시장은 유형, 약물 종류, 유통 채널 및 지역별로 분류됩니다.
• 시장은 유형에 따라 좌심부전, 우심부전, 고출력 심부전의 세 가지 범주로 나뉩니다. 좌심부전이 더 흔하며, 더 세분화하여 박출률 감소형 심부전(HFrEF)과 박출률 유지형 심부전(HFpEF)으로 나뉩니다.
• 시장은 약물 종류에 따라 ACE 억제제, 안지오텐신2 수용체 길항제, 베타 차단제, 이뇨제, 알도스테론 길항제, 강심제, 기타 2가지로 분류됩니다. 안지오텐신2 수용체 길항제가 시장을 독점하고 있으며, 예측 기간 동안에도 우위를 유지할 것으로 보입니다. 안지오텐신2 수용체 길항제(ARB)는 울혈성심부전(CHF)을 포함한 다양한 심혈관 질환의 치료에 사용되는 필수 약물군으로, 특히 ACE 억제제를 견딜 수 없는 환자들에게 사용됩니다.
• 시장은 유통 채널에 따라 병원 약국, 소매 약국, 온라인 약국의 두 가지 범주로 나뉩니다. 병원 약국 부문이 시장을 독점하고 있습니다. 병원 약국은 울혈성심부전(CHF)을 포함한 다양한 질병에 대한 치료제의 유통 및 조제에 필수적입니다.

울혈성심부전 치료제 시장 - 지리적 인사이트

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역은 비지니스를 가져오는 국가에 따라 더 세분화됩니다. 북미는 의료비 급증, 심장 건강에 대한 높은 인식, 의료 서비스 증가로 인해 울혈성심부전 치료제 시장의 성장을 주도할 것으로 예상됩니다. 미국은 1인당 의료비 지출이 세계 최고 수준입니다. 이러한 막대한 지출은 필연적으로 의약품과 치료법에 대한 접근성을 증가시킵니다. 메디케어-메디케이드 서비스 센터에 따르면 미국의 의료비는 2021년 2.7% 성장해 4조 3,000억 달러, 1인당 1만 2,914달러에 달할 것으로 예상됩니다. 국내총생산에서 의료비가 차지하는 비중은 18.3%입니다. 유럽은 연구개발에 대한 지출 증가로 인해 이 시장 성장에서 두 번째로 큰 지역을 차지하고 있습니다.

울혈성심부전 치료제 시장 - 경쟁 상황

울혈성심부전(CHF) 치료제 시장에는 기존 거대 제약사부터 최첨단 치료제에 집중하는 신규 진입자까지 다양한 기업들이 진출해 있습니다. 여러 유명 제약회사들이 새로운 CHF 치료제를 개발하고 있으며, 특히 초기 CHF 치료제의 특허가 만료됨에 따라 제네릭 의약품 시장도 크게 성장하고 있습니다. 추가하기 위해 중소기업을 인수하거나 제휴를 하고 있습니다. 예를 들어, 미국과 캐나다 이외 지역에서는 MSD로 알려진 머크(Merck)는 2023년 3월 6일 미국 식품의약국(FDA)으로부터 증상성 만성 심부전 및 박출률이 45% 미만인 성인에서 심부전으로 인한 입원 또는 외래에서 정맥 이뇨가 필요한 심혈관 사망 및 심부전으로 인한 입원 위험을 줄이기 위해 수용성 구아닐산시클라아제(sGC) 자극제 VERQUVO를 승인받았다고 밝혔습니다.

목차

제1장 울혈성심부전 치료제 시장 개요

• 조사 범위
• 시장 추정 연수

제2장 주요 요약

• 시장 내역
• 경쟁 인사이트

제3장 울혈성심부전 치료제 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 울혈성심부전 치료제 업계 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 매핑
• 규제 체계 분석

제5장 울혈성심부전 치료제 시장 : COVID-19의 영향 분석

• 신종 코로나바이러스 감염증 이전의 영향 분석
• 신종 코로나바이러스 감염증 후의 영향 분석

제6장 울혈성심부전 치료제 시장 상황

• 울혈성심부전 치료제 시장 점유율 분석, 2022년
• 주요 제조업체별 내역 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 울혈성심부전 치료제 시장 - 유형별

• 개요
  • 유형별 부문 점유율 분석
  • 좌측 심부전
  • 우측 심부전
  • 고심박출성 심부전

제8장 울혈성심부전 치료제 시장 - 약제 클래스별

• 개요
  • 약제 클래스별 부문 점유율 분석
  • ACE 억제제
  • 안지오텐신 2 수용체 차단제
  • 베타 차단제
  • 이뇨제
  • 알도스테론 길항제
  • 변력약
  • 기타

제9장 울혈성심부전 치료제 시장 - 유통 채널별

• 개요
  • 유통 채널별 부문 점유율 분석
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제10장 울혈성심부전 치료제 시장 - 지역별

• 서론
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제11장 주요 벤더 분석 - 울혈성심부전 치료제 업계

• 경쟁 대시보드
• 기업 개요
  • Bayer AG
  • Novartis AG
  • Merck &Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson &Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S

제12장 애널리스트의 전방위 전망

ksm

영문 목차

영문목차

REPORT HIGHLIGHT

Congestive heart failure drugs Market size was valued at USD 6,600.9 Million in 2022, expanding at a CAGR of 15.8% from 2023 to 2030.

Congestive heart failure (CHF) is a complex clinical illness caused by any anatomical or functional cardiac problem that inhibits the heart's ability to fill with or pump enough blood throughout the body. The most effective therapy for CHF is generally determined by the underlying cause of the heart failure, its severity, and any other medical disorders the patient may have. The goal of treatment for chronic congestive heart failure (CHF) is to enhance symptom management and quality of life, reduce hospitalizations, and lower overall mortality.

Congestive heart failure drugs Market - Market Dynamics:

• A rise in the geriatric population and an increase in the incidence of hypertension, obesity, and diabetes are expected to augment industry growth.

• Elderly people have more comorbid diseases and frequently take many drugs, making them more vulnerable to drug interactions and conditions that exacerbate heart failure. Obesity is also linked to other health issues such as sleep apnea and diabetes, both of which raise the risk of heart failure. According to the World Health Organization, 39 million children under the age of 5 were overweight or obese in 2020. As rising economies' healthcare infrastructure develops, there is an increasing need for modern medical treatments, especially medications for illnesses such as CHF providing growth opportunities for the market. However, Advanced treatments such as cardiac resynchronization therapy (CRT) and other medical devices can occasionally reduce the need for pharmaceuticals.

Congestive heart failure drugs Market - Key Insights:

• As per the analysis shared by our research analyst, the global Congestive heart failure drugs market is estimated to grow annually at a CAGR of around 15.8% over the forecast period (2023-2030)

• The Congestive heart failure drugs industry is projected to grow at a significant rate due to the growing awareness of sustainable growth

• Based on type segmentation, Left-sided Heart Failure was predicted to show maximum market share in the year 2022

• Based on drug class segmentation, Angiotensin II Receptor Blockers (ARBs were the leading type in 2022

• Based on distribution channel segmentation, hospital Pharmacies were the leading type in 2022

• On the basis of region, North America was the leading revenue generator in 2022

Congestive Heart Failure Drugs Market- Segmentation Analysis:

• The Global Congestive Heart Failure Drugs Market is segmented on the basis of Type, Drug Class, Distribution Channel, and Region.

• The market is divided into three categories based on type: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure. Left-sided heart failure is more prevalent, and it is further subdivided into heart failures with reduced ejection fraction (HFrEF) and heart failures with maintained ejection fraction (HFpEF).

• The market is divided into two categories based on Drug Class: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others. The Angiotensin 2 Receptor Blockers dominate the market and are likely to maintain their dominance during the forecast period. Angiotensin II Receptor Blockers (ARBs) are an essential class of drugs used to treat a variety of cardiovascular disorders, including congestive heart failure (CHF), particularly in patients who cannot tolerate ACE inhibitors.

• The market is divided into two categories based on Distribution Channels: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies sector dominates the market. Hospital pharmacies are essential in the distribution and dispensing of medications for a variety of diseases, including congestive heart failure (CHF).

Congestive heart failure drugs Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to drive the growth of the Congestive Heart Failure Drugs Market, due to a Surge in medical spending, high awareness about cardiac health, and an increase in the availability of healthcare services. The United States has one of the world's largest per capita healthcare expenses. This significant expenditure inevitably increases access to medications and therapies. According to the Center for Medicare and Medicaid Service, U.S. healthcare spending will grow 2.7 percent in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3 percent. Europe held the second largest region for the growth of this market, due to a rise in spending on research & development activities.

Congestive heart failure drugs Market- Competitive Landscape:

The market for congestive heart failure (CHF) medications has seen a variety of participants, ranging from established pharmaceutical behemoths to newer entrants focused on cutting-edge therapy. While several prominent pharmaceutical companies are developing novel treatments for CHF, there is also a substantial market for generic medications, especially because many of the earlier CHF treatments have had their patents expire. The CHF medicine market has seen a sufficient number of mergers and acquisitions, with larger players acquiring or collaborating with smaller companies to bring novel treatments into their pipelines. For Example, on 6 march 2023, Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

Recent Developments:

On March 1, 2023, Amgen (NASDAQ: AMGN) announced new Repatha (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, a siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET KEY PLAYERS

• Bayer AG
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Pfizer, Inc.
• Johnson & Johnson Services, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Novo Nordisk A/S

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY TYPE

• Left-sided Heart Failure
• Right-sided Heart Failure
• High-output Heart Failure

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DRUG CLASS

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DISTRIBUTION CHANNEL

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY REGION

• North America
• The U.S.
• Canada

• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe

• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC

• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM

• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Congestive Heart Failure Drugs Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Congestive Heart Failure Drugs Market Snippet by Type
  • 2.1.2. Congestive Heart Failure Drugs Market Snippet by Drug Class
  • 2.1.3. Congestive Heart Failure Drugs Market Snippet by Distribution Channel
  • 2.1.4. Congestive Heart Failure Drugs Market Snippet by Country
  • 2.1.5. Congestive Heart Failure Drugs Market Snippet by Region
• 2.2. Competitive Insights

3. Congestive Heart Failure Drugs Key Market Trends

• 3.1. Congestive Heart Failure Drugs Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Congestive Heart Failure Drugs Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Congestive Heart Failure Drugs Market Opportunities
• 3.4. Congestive Heart Failure Drugs Market Future Trends

4. Congestive Heart Failure Drugs Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Congestive Heart Failure Drugs Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Congestive Heart Failure Drugs Market Landscape

• 6.1. Congestive Heart Failure Drugs Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Congestive Heart Failure Drugs Market - By Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
  • 7.1.2. Left-sided Heart Failure
  • 7.1.3. Right-sided Heart Failure
  • 7.1.4. High-output Heart Failure

8. Congestive Heart Failure Drugs Market - By Drug Class

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
  • 8.1.2. ACE Inhibitors
  • 8.1.3. Angiotensin 2 Receptor Blockers
  • 8.1.4. Beta Blockers
  • 8.1.5. Diuretics
  • 8.1.6. Aldosterone Antagonists
  • 8.1.7. Inotropes
  • 8.1.8. Others

9. Congestive Heart Failure Drugs Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Retail Pharmacies
  • 9.1.4. Online Pharmacies

10. Congestive Heart Failure Drugs Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Congestive Heart Failure Drugs Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Congestive Heart Failure Drugs Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Congestive Heart Failure Drugs Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Congestive Heart Failure Drugs Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Congestive Heart Failure Drugs Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Congestive Heart Failure Drugs Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Bayer AG
  • 11.2.2. Novartis AG
  • 11.2.3. Merck & Co., Inc.
  • 11.2.4. AstraZeneca
  • 11.2.5. Bristol-Myers Squibb Company
  • 11.2.6. Amgen Inc.
  • 11.2.7. Boehringer Ingelheim International GmbH
  • 11.2.8. Pfizer, Inc.
  • 11.2.9. Johnson & Johnson Services, Inc.
  • 11.2.10. Otsuka Pharmaceutical Co., Ltd.
  • 11.2.11. Eli Lilly and Company
  • 11.2.12. Novo Nordisk A/S

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us

관련자료